Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease

NCTID	NCT03720418 (View at clinicaltrials.gov)
Description	This study consists of two parts. Part A will evaluate the safety and tolerability of multiple doses of OXB-102 (AXO-Lenti-PD) in participants with Parkinson's disease. Part B will assess the safety and efficacy of the selected dose of OXB-102 in participants with Parkinson's disease. (Show More)
Development Status	Inactive
Indication	Parkinson Disease
Disease Ontology Term	DOID:14330
Compound Name	OXB-102
Compound Alias	AXO-Lenti-PD, ProSavin
Compound Description	EIAV.CMV.TH-CH1.AADC
Sponsor	Sio Gene Therapies
Funder Type	Industry
Recruitment Status	Terminated
Enrollment Count	6
Results Posted	Not Available

Target Gene/Variant	TH-GCH1.DDC (tricistronic)
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Intraparenchymal (putamen)
Drug Product Type	Viral vector
Target Tissue/Cell	Striatal neurons
Delivery System	Viral transduction
Vector Type	EIAV
Editor Type	none
Dose 1	1.9E7 TU
Dose 2	4.0E7 TU
Dose 3	1E8 TU
Dose 4
Dose 5

No.of Trial Sites	3
Locations	United Kingdom,France

Has US IND	False
FDA Designations
Recent Updates	Axovant rebranded as Sio Gene Therapies, the company dissolved in 2023, returned rights to Oxford Biomedica which has shelved the program